Centessa Pharmaceuticals (CNTA) Income from Continuing Operations (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Income from Continuing Operations of 79241000.0 for Q1 2026, down 203.2% year-over-year from 76784825.74 in Q1 2025, and down 19.77% quarter-over-quarter from 66163000.0 in Q4 2025.
Centessa Pharmaceuticals (CNTA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Centessa Pharmaceuticals (CNTA) has 7 years of Income from Continuing Operations data on file, last reported at 79241000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 79241000.0, down 203.2% year-over-year; the trailing twelve-month figure through Mar 2026 was 250638000.0 (down 11.97% YoY), and the FY2025 annual result was 197532000.0, up 16.21% from the prior year.
- Income from Continuing Operations eased to 79241000.0 in Q1 2026 per CNTA's latest filing, from 66163000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 24886000.0 in Q2 2023 and troughed at 111329000.0 in Q4 2024.
- A 5-year average of 51756647.06 and a median of 50343000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations soared 77.17% in 2022, then slumped 203.2% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 43173000.0 in 2022, then gained by 14.68% to 36837000.0 in 2023, then tumbled by 202.22% to 111329000.0 in 2024, then surged by 40.57% to 66163000.0 in 2025, then retreated by 19.77% to 79241000.0 in 2026.
- Business Quant data shows CNTA's Income from Continuing Operations at 79241000.0 in Q1 2026, 66163000.0 in Q4 2025, and 54891000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Centessa Pharmaceuticals | 6.15 Bn | 6.15 Bn | - | -79.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.24 Mn |
| Dec 31, 2025 | -66.16 Mn |
| Sep 30, 2025 | -54.89 Mn |
| Jun 30, 2025 | -50.34 Mn |
| Mar 31, 2025 | -26.14 Mn |
| Dec 31, 2024 | -111.33 Mn |
| Sep 30, 2024 | -42.57 Mn |
| Jun 30, 2024 | -43.82 Mn |
| Mar 31, 2024 | -38.05 Mn |
| Dec 31, 2023 | -36.84 Mn |
| Sep 30, 2023 | -38.65 Mn |
| Jun 30, 2023 | -24.89 Mn |
| Mar 31, 2023 | -50.71 Mn |
| Dec 31, 2022 | -43.17 Mn |
| Sep 30, 2022 | -53.92 Mn |
| Jun 30, 2022 | -64.66 Mn |
| Mar 31, 2022 | -54.50 Mn |
| Dec 31, 2021 | -60.77 Mn |
| Sep 30, 2021 | -40.16 Mn |
| Jun 30, 2021 | -41.45 Mn |